The Canada Artificial Intelligence in Drug Discovery Market was valued at $66.3 Million in 2024 and projected to reach to $216.1 Million by 2029, representing a compound annual growth rate of 26.7%. Canada's AI in drug discovery market is poised for significant expansion through 2029, driven by increasing adoption among pharmaceutical companies, biotechnology firms, and academic research centers.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Canada's AI in drug discovery market is valued at $66.3 million in 2024, with projections reaching $216.1 million by 2029, demonstrating a robust 26.7% CAGR that underscores the country's commitment to life sciences innovation.
Canada is establishing itself as a premier life sciences innovation hub, with pharmaceutical companies and research institutions increasingly integrating AI-powered solutions into their drug discovery pipelines to accelerate development timelines.
While the global AI in drug discovery market grows at 29.9% CAGR, Canada's 26.7% growth rate reflects strong regional adoption driven by government support, academic excellence, and venture capital investment in biotech startups.
Canadian research institutions and biotech firms are leveraging AI technologies to enhance drug candidate identification, reduce development costs, and improve success rates in clinical trials, positioning the nation as a competitive player in global drug discovery.
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
GPU-accelerated computing, BioNeMo foundation models, generative AI, molecular simulation, and high-performance computing platforms supporting target discovery, protein engineering, molecular design, and virtual screening | Faster AI model training | Accelerated molecular discovery | Reduced computational time | Scalable drug discovery workflows | Improved research productivity |
|
|
Physics-based molecular modeling, computational chemistry, AI-assisted drug design, virtual screening, and lead optimization through an integrated computational drug discovery platform | Higher prediction accuracy | Improved lead optimization | Lower experimental costs | Accelerated candidate selection | Increased probability of clinical success |
|
|
Generative AI-powered target identification, de novo molecule generation, biomarker discovery, and end-to-end drug discovery through the Pharma.AI platform integrating biology, chemistry, and clinical data | Shortened discovery timelines | Rapid identification of novel drug candidates | Improved target validation | Enhanced R&D efficiency | Reduced drug development costs |
|
|
AI-driven phenomics platform combining high-content cellular imaging, machine learning, automated experimentation, and large-scale biological datasets for target discovery and therapeutic development | Faster target identification | Improved biological insights | Higher-quality candidate selection | Increased experimental throughput | Enhanced translational research efficiency |
|
|
AI foundation models, protein structure prediction, cloud-based AI infrastructure, and multimodal data analytics supporting drug target discovery, molecular modeling, and biomedical research | Improved biological understanding | Accelerated target discovery | Scalable AI infrastructure | Enhanced predictive modelling | Faster scientific innovation |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | ANTIBODY & OTHER BIOLOGICS DESIGN (Type) |
| Forecast Period | 2024-2029 |
| Growth Rate | CAGR of 29.9% from 2024 to 2029 |
| Largest Segment | PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES (End User) |
| Market Size Base Year (Billions) | ~USD 1.86 (2024) |
| Revenue Forecast (Billions) | ~USD 6.89 (2029) |
| Segments Covered | Process, Use Case, Type, Therapeutic Area, Player Type, Ai Tool, Deployment, End User, Process 2022-2029 |
9 segment dimensions are covered across the global market.
Canada's AI drug discovery market was valued at $66.3 million in 2024 and is projected to reach $216.1 million by 2029.
Canada's AI drug discovery market is expected to grow at a compound annual growth rate (CAGR) of 26.7% from 2024 to 2029.
Canadian pharmaceutical companies, biotech startups, and academic research institutions are the primary drivers of AI drug discovery adoption in Canada.
Key growth factors in Canada include government R&D funding, strong academic institutions, public-private partnerships, and a supportive regulatory environment for innovation.
Canada's 26.7% CAGR is slightly below the global average of 29.9%, but Canada's market is growing steadily as a regional leader in North America.
The study involved significant activities in estimating the current size of the AI in drug discovery market. Exhaustive secondary research was done to collect information on the market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the AI in drug discovery market.
This research study involved the wide use of secondary sources, directories, and databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva; white papers, annual reports, and Companies House documents; investor presentations; and the SEC filings of companies. The market for the companies offering AI in drug discovery solutions is arrived at by secondary data available through paid and unpaid sources, analyzing the product portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases.
Various secondary sources were referred to in the secondary research process to identify and collect information related to the study. These sources included annual reports, press releases, investor presentations of AI in drug discovery vendors, forums, certified publications, and whitepapers. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and technology-oriented perspectives.
In the primary research process, various sources from the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources are mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess prospects.
Primary research was conducted to identify segmentation types; industry trends; key players; and key market dynamics such as drivers, restraints, opportunities, challenges, industry trends, and strategies adopted by key players. After the complete market engineering (calculations for market statistics, market breakdown, market size estimations, market forecasting, and data triangulation), extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at.
In the complete market engineering process, the top-down and bottom-up approaches and several data triangulation methods were extensively used to perform the market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list the key information/insights throughout the report.
Breakdown of the Primary Respondents:

Note: Other designations include sales managers, marketing managers, and product managers.
Note: Tiers are defined based on a company’s total revenue as of 2025: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
The market size estimates and forecasts provided in this study are derived through a mix of the bottom-up approach (revenue share analysis of leading players) and the top-down approach (assessment of utilization/adoption/penetration trends by offering, function, application, deployment, tools, end user, and region).

After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and sub-segment, the data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the AI in drug discovery market.
The AI in drug discovery market comprises artificial intelligence-based software platforms and computational solutions that accelerate early-stage drug discovery by enabling target identification, lead optimization, candidate selection, and drug repurposing. These solutions leverage technologies such as machine learning, deep learning, and generative AI to improve R&D efficiency, reduce costs, and shorten drug development timelines.
With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:
Further breakdown of the Rest of Europe’s AI in drug discovery market into Denmark, Norway, and others
Further breakdown of the Rest of Asia Pacific AI in drug discovery market into Vietnam, New Zealand, Australia, South Korea, and others
Detailed analysis and profiling of additional market players (up to 5)
Full forecast, segment splits, and company analysis for all Artificial Intelligence in Drug Discovery Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report